Buy Pfizer Stock At $24?
1. Pfizer exceeded Q2 earnings expectations with $0.78 per share on $14.65 billion revenue. 2. Full-year guidance raised; strong sales growth in key products like Paxlovid and Vyndaqel. 3. PFE has a trailing P/E ratio of 8, below its five-year average of 13. 4. Investor sentiment remains cautious due to uncertainty in drug pipeline performance. 5. Stock is currently seen as undervalued at approximately $24 despite recent volatility.